From Growth factor shows promise for Phelan-McDermid syndrome
"Last week, a separate set of researchers announced that the drug appears to be safe and effective in a trial of 53 adolescents and adults with Rett syndrome."
The inference is that IGF-1 was the drug being used instead of NNZ-2566. Only later on do you learn that:
"The Rett trial uses a modified form of IGF-1 that includes only the first three amino acids, but which may induce production of the full-length form in the brain"
I have noticed in a number of articles IGF-1 was being hyped and NNZ-2566 downplayed or not mentioned (as in the above announcement). To me IGF-1 is a competitor.
- Forums
- ASX - By Stock
- Wider autism efficacy potential for nnz-2566
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.00%
!
$14.02

From Growth factor shows promise for Phelan-McDermid syndrome...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.02 |
Change
0.000(0.00%) |
Mkt cap ! $1.745B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 295 | $14.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.74 | 79 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 40 | 14.050 |
1 | 72 | 14.020 |
6 | 1359 | 14.000 |
2 | 317 | 13.990 |
1 | 98 | 13.930 |
Price($) | Vol. | No. |
---|---|---|
12.740 | 79 | 1 |
13.170 | 1005 | 3 |
13.360 | 74 | 1 |
13.500 | 12500 | 3 |
13.810 | 79 | 1 |
Last trade - 09.58am 08/07/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
AGC
AUSTRALIAN GOLD AND COPPER LTD
Glen Diemar, MD
Glen Diemar
MD
SPONSORED BY The Market Online